T he renin-angiotensin system and the kallikrein-kinin system contribute to fluid homeostasis and blood pressure regulation. The renin-angiotensin system is composed of 2 arms with opposing functions. The pressor arm, represented by the angiotensin type 1 receptor (AT 1 R), angiotensin-converting enzyme (ACE), and angiotensin II, is responsible for the vasoconstrictive, proliferative, fibrotic, and hypertensive effects of the renin-angiotensin system. In contrast, the second arm exerts depressor and cardiovascular protective effects through angiotensin-(1-7) (Ang-(1-7)), the Ang-(1-7)-specific receptor Mas that transduces the main physiological actions of Ang-(1-7), and ACE2 that catalyzes the generation of Ang-(1-7) from angiotensin II. [1] [2] [3] Bradykinin, generated by the kallikrein-kinin system, exerts cardioprotective, vasodilatory, and depressor properties through B 2 receptor (B 2 R) stimulation. 4, 5 Several studies showed the existence of a cross talk between the renin-angiotensin system and kallikrein-kinin system. 6, 7 For instance, kallikrein not only catalyzes the generation of kinin from kininogen, but also acts as a prorenin-activating enzyme leading to an increase in angiotensin II. 6 In addition, ACE not only generates the vasopressor angiotensin II but also responsible for the proteolytic degradation of bradykinin. 6, 7 Not only was a cross talk between both systems reported at the enzymatic level, but also between the components of these systems. For example, Ang-(1-7) exerts kinin-like effects and Abstract-Bradykinin B 2 receptor (B 2 R) and angiotensin-(1-7) Mas receptor (MasR)-mediated effects are physiologically interconnected. The molecular basis for such cross talk is unknown. It is hypothesized that the cross talk occurs at the receptor level. We investigated B 2 R-MasR heteromerization and the functional consequences of such interaction. B 2 R fused to the cyan fluorescent protein and MasR fused to the yellow fluorescent protein were transiently coexpressed in human embryonic kidney293T cells. Fluorescence resonance energy transfer analysis showed that B 2 R and MasR formed a constitutive heteromer, which was not modified by their agonists. B 2 R or MasR antagonists decreased fluorescence resonance energy transfer efficiency, suggesting that the antagonist promoted heteromer dissociation. B 2 R-MasR heteromerization induced an 8-fold increase in the MasR ligandbinding affinity. On agonist stimulation, the heteromer was internalized into early endosomes with a slower sequestration rate from the plasma membrane, compared with single receptors. B 2 R-MasR heteromerization induced a greater increase in arachidonic acid release and extracellular signal-regulated kinase phosphorylation after angiotensin-(1-7) stimulation, and this effect was blocked by the B 2 R antagonist. Concerning serine/ threonine kinase Akt activity, a significant bradykinin-promoted activation was detected in B 2 R-MasR but not in On the other hand, the Ang-(1-7) effects such as the neuroinhibitory action on noradrenergic neurotransmission, 13 the stimulatory effect on nitric oxide generation, 14 or the facilitation of the baroreflex control of the heart rate 15 completely disappeared when the specific bradykinin receptor subtype B 2 was blocked. However, in not all circumstances, the effects of these peptides depend on both B 2 R and MasR. 16 Despite that, the function and the molecular basis for such cross talk are still unknown.
It could be hypothesized that the cross talk between both pathways occurs at the receptor level. Indeed, both B 2 R and MasR belong to the G-protein-coupled receptor (GPCR) family. GPCRs exist as homo-or hetero-oligomers. Such structural organization has been found to be essential for receptor function. GPCR oligomerization affects important receptor functions like biosynthesis, plasma membrane diffusion or velocity, ligand-binding, pharmacology, signaling, and trafficking properties. [17] [18] [19] Taking into account that bradykinin actions are blocked by an MasR antagonist or when MasR is knocked down, or that Ang-(1-7) response disappears when B 2 R is blocked, we hypothesized that B 2 R and MasR may interact directly through a heteromer formation. Our aim was to investigate the heteromerization between B 2 R and MasR and to determine its functional consequences.
Materials and Methods

Cell Culture and Transfection
Human embryonic kidney293T cells obtained from the American Type Culture Collection were grown in high-glucose Dulbecco Modified Eagle Medium, 10 mg/mL sodium pyruvate, 2 mmol/L l-glutamine, 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 μg/ mL streptomycin at 37° C in a humidified atmosphere at 95% air and 5% CO 2 . Cells were transiently transfected with cDNA (3 µg/9.5 cm 2 tissue culture well) encoding for MasR fused to enhanced yellow fluorescence protein (MasR-yellow fluorescence protein [YFP] ) and B 2 R fused to enhanced cyan fluorescence protein (B 2 R-cyan fluorescence protein [CFP]) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions and were used 48 hour post transfection. MasR-YFP cDNA was obtained as previously described. 20 B 2 R-CFP cDNA was a gift from Dr Faussner (LudwigMaximilians-University Munich, Munich, Germany). This construct was subcloned into BamHI-XhoI sites of pcDNA3.1 plasmid. The cloned genes were confirmed by restriction analysis and sequencing. Physical and biological containment of both recombinant plasmids conform to the National Institutes of Health guidelines.
Human glomerular endothelial cells were kindly gifted by Dr María Marta Amaral. Human glomerular endothelial cells were isolated as previously described 21 from kidneys removed from different pediatric patients undergoing nephrectomies performed at Hospital Nacional "Alejandro Posadas," Buenos Aires, Argentina (written informed consent was obtained from the next of kin, caretakers, or guardians on behalf of the minor/children participants involved). The Ethics Committee of the University of Buenos Aires approved the use of human renal tissues for research purposes. Detailed methods are provided in the online-only Data Supplement.
Data Analysis
The results are presented as mean±SEM. One-way ANOVA computation combined with the Bonferroni test was used to analyze data with unequal variance between each group. A probability level of 0.05 was considered significant.
Results
B 2 R Interacts With MasR
B 2 R-MasR heteromerization was investigated by fluorescence resonance energy transfer (FRET), 22 so we generated fusion proteins of the B 2 R and MasR sequences tagged at their carboxyl terminus to the enhanced cyan fluorescence protein and, respectively (Data Supplement). Human embryonic kidney293T cells were cotransfected with B 2 R-CFP and MasR-YFP, and interaction between B 2 R and MasR was evaluated by FRET measured by acceptor photobleaching. 22 Figure 1A shows a representative FRET experiment. Fluorescence of YFP and CFP was observed in the cell membrane and cytoplasm of human embryonic kidney293T cells coexpressing B 2 R-CFP and MasR-YFP, at prephotobleaching. Acceptor photobleaching resulted in a decrease in YFP fluorescence and in a positive FRET ( Figure 1B) . To quantify FRET, we calculated the apparent FRET efficiency, which for tight interactions is proportional to the fraction of the donor in complex with the acceptor. For cells transiently coexpressing B 2 R-CFP and MasR-YFP with similar donor enhanced cyan fluorescence protein to acceptor enhanced yellow fluorescence protein ratio, a mean apparent FRET efficiency of 0.31±0.02 was measured ( Figure 1C ) demonstrating that both B 2 R and MasR constitutively interact by a heteromer formation.
To further corroborate FRET specificity between B 2 R and MasR, FRET was evaluated in cells transiently coexpressing B 2 R-CFP and MasR-YFP with the native B 2 R (without an enhanced cyan fluorescence protein moiety) or with the native MasR (without an enhanced yellow fluorescence protein moiety). If an interaction between B 2 R and MasR exists, a decrease in FRET apparent efficiency would be expected because of the formation of heteromers between B 2 R-CFP and untagged Mas or MasR-YFP and untagged B 2 R. As it is shown in Figure 1C , the presence of the untagged receptors resulted in a significant reduction in FRET apparent efficiency, demonstrating that untagged receptors are competing with tagged receptors for heteromer formation, thus reinforcing the interaction between both B 2 R and MasR. Altogether, these results show that FRET arises from the interaction between the receptor moieties of the fusion proteins, and hence demonstrate the existence of constitutive B 2 R-MasR heteromers.
The influence of ligands on FRET efficiency was investigated by incubating the cells cotransfected with B 2 R-CFP plus MasR-YFP with 1 µmol/L bradykinin or Ang-(1-7), for 15 minutes at 37°C, before FRET analysis. The formation of B 2 R-MasR heteromer was not altered by either of the agonists because FRET was not modified when the cells were stimulated with bradykinin or Ang-(1-7) ( Figure 1D ), demonstrating that the oligomerization state of B 2 R-MasR complexes is not modulated by the agonist. On the contrary, the addition of B 2 R or MasR antagonists decreased FRET efficiency to ≈50% of the initial value, indicating that the antagonist promoted the dissociation of the heteromer ( Figure 1D ). Figure 2B ). These results suggested that heteromerization modified the pharmacological properties of MasR but not of B 2 R.
B 2 R-MasR Heteromer Internalizes Into Early Endosomes on Agonist Stimulation
To determine whether heteromerization affects the trafficking properties of these receptors, agonist-induced redistribution of receptors from the cell surface (ie, internalization) was examined. To investigate whether B 2 R-MasR heteromer was targeted to early endosome, B 2 R-CFP-and MasR-YFP-cotransfected cells were stimulated with 1 µmol/L Ang-(1-7) during 15 minutes, and then colocalization with the early endosome marker Rab5 was evaluated. After Ang-(1-7) treatment, B 2 R and MasR internalization was observed as small bright spots within the cell ( Figure S2A and S2B in the online-only Data Supplement), in a distribution pattern that is characteristic of receptors located in intracellular endocytic vesicles. Quantitative colocalization analysis revealed Pearson correlation coefficient >0.6 indicating that both B 2 R and MasR were colocalized. Thus, B 2 R and Mas cointernalized on ligand stimulation. We also evaluated whether the heteromer is endocyted to early endosome on ligand stimulation. The analysis revealed that a fraction of the oligomer B 2 R-MasR colocalized with the early endosome marker Rab5 (Figure S2C and S2D ; Pearsons correlation coefficient: 0.82±0.1, P<0.01 by 1-tail Wilcoxon matched pairs signed ranks test). Similar results were observed after bradykinin stimulation. Altogether, these results showed that the oligomer B 2 R-MasR was targeted mostly to early endosomes after agonist stimulation.
Ang-(1-7) Induces B 2 R Internalization When B 2 R-MasR Heteromer Is Formed
To further confirm the existence of B 2 R-MasR heteromer and its internalization, we investigated whether selective stimulation of one of the receptor promotes cointernalization of both receptors. To induce receptor internalization, cells were stimulated with the selective B 2 R agonist bradykinin (1 µmol/L) or the selective MasR agonist Ang- (1-7) (1 µmol/L) for 30 minutes. The amount of B 2 R or MasR present in the plasma membrane after agonist stimulation was evaluated by radioligand-binding assays. B 2 R-transfected cells stimulated with bradykinin or MasRtransfected cells stimulated with Ang-(1-7) showed a significant decrease in the amount of receptor present in the plasma membrane ( Figure 3A and 3B, respectively), indicating that the receptor was internalized on agonist stimulation. When B 2 R-MasR-transfected cells were stimulated with bradykinin, there was a decrease of 91±4% in B 2 R and 53±3% in MasR in the plasma membrane ( Figure 3C and  3D) . Conversely, when B 2 R-MasR-transfected cells were stimulated with Ang-(1-7), there was a decrease of 58±4% in B 2 R and 82±6% in MasR present in the plasma membrane ( Figure 3C and 3D) .
These results clearly demonstrate that in cells coexpressing both receptors, the selective stimulation of one of the GPCRs promotes cointernalization of both receptors.
B 2 R-MasR Heteromerization Results in a Decreased Rate of Ang-(1-7)-Mediated MasR Sequestration
Because B 2 R-MasR interaction may lead to changes in the rate of receptor sequestration from the plasma membrane after agonist stimulation, we evaluated the percentage of internalized MasR after Ang-(1-7) treatment. Cells were stimulated with Ang-(1-7) (1 µmol/L) during different times for the time intervals ranging from 5 to 40 minutes, and the amount of MasR present in the plasma membrane was determined by radioligand-binding assay. Receptor sequestration was then defined as the decrease in specific 
B 2 R-MasR Heteromerization and Downstream Signaling
We determined whether heteromerization leads to alterations in functional coupling. Arachidonic acid (AA) release in response to bradykinin or Ang-(1-7) was examined in cells expressing individual or both receptors. Cells expressing both B 2 R and MasR showed an increase in AA release under basal condition which was ≈2-fold higher than that observed in cells expressing one of the receptors ( Figure  4A ). Bradykinin or Ang-(1-7) treatment resulted in a significant increase in AA release in cells transiently expressing B 2 R or MasR alone or together, being the effect elicited by Ang-(1-7) greater in cells expressing both receptors ( Figure 4A ).
The increase in AA release induced by Ang-(1-7) (1 µmol/L) in cells coexpressing both B 2 R and MasR was blocked by the B 2 R antagonist Hoe 140 (10 µmol/L). Conversely, the increase in AA release induced by bradykinin in cells Figure 4B ). These results support B 2 R-MasR heteromerization.
We also investigated whether B 2 R-MasR heteromerization affects extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase activation. Bradykinin (1 µmol/L) had no effect on ERK phosphorylation in cells transiently expressing B 2 R alone, whereas Ang-(1-7) (1 µmol/L) induced a significant increase in ERK phosphorylation in cells transiently expressing MasR alone ( Figure  4C ). Cells transiently coexpressing both B 2 R and MasR showed no change in ERK phosphorylation under basal condition compared with that observed in cells expressing one of the receptors (Figure S3A ), indicating that the B 2 R-MasR heteromer does not modify constitutive ERK activation. In cells expressing both B 2 R and MasR, ERK phosphorylation was not modified by bradykinin treatment, but it was increased in response to Ang-(1-7), and this effect was greater compared with cells expressing only MasR. The Ang-(1-7)-stimulated ERK phosphorylation was prevented by pretreatment with the B 2 R antagonist ( Figure 4D ).
The effect of B 2 R-Mas heteromerization on serine/ threonine kinase Akt phosphorylation was also evaluated. Bradykinin or Ang-(1-7) had no effect on Akt phosphorylation in cells transiently expressing B 2 R or MasR alone, respectively ( Figure 4E ). Cells transiently coexpressing both B 2 R and MasR showed no change in Akt phosphorylation under basal condition compared with that observed in cells expressing one of the receptors ( Figure S3B ). Conversely, bradykinin induced an increase in Akt phosphorylation in cells expressing both B 2 R and MasR, and this effect was partially prevented by pretreatment with the MasR antagonist ( Figure 4F) .
Altogether, these data support the presence of B 2 R-MasR heteromerization and the consequences on downstream signaling. 
BK or Ang-(1-7) Induces Antiproliferative Effect Only When B 2 R-MasR Heteromer is Formed
We tested whether B 2 R-MasR heteromerization may lead to changes in the biological response, eg, cellular proliferation. Cells expressing individual or both receptors did not show differences in cellular growth ( Figure 5A ). Bradykinin or Ang-(1-7) (100 nmol/L or 1 µmol/L) were without effect on cellular proliferation in cells expressing only B 2 R or MasR, respectively ( Figure S4 and Figure 5B , respectively). However, in cells coexpressing both receptors, 1 µmol/L bradykinin or Ang-(1-7) induced a decrease in cellular proliferation (43±5% reduction in bradykinintreated cells and 36±6% reduction in Ang-(1-7)-treated cells; Figure 5B ). There was a tendency to reduce cellular proliferation after incubation with 100 nmol/L bradykinin or Ang-(1-7) ( Figure S4 ) not statistically significant. This reduction was lower than that observed with higher concentrations of the ligands. Thus, bradykinin or Ang- (1-7) induced an antiproliferative response when B 2 R heteromerized with MasR.
B 2 R-MasR Heteromer Formation in Physiological Conditions
To establish that our results are not specific to transfected human embryonic kidney293T cells and that B 2 R-MasR oligomerization also occurs in cells that natively express both receptors, we evaluated B 2 R-MasR interaction in mesenteric vascular bed from rats. On immunoprecipitation of the B 2 R from mesenteric vascular bed lysate, we observed coprecipitation of the MasR ( Figure 6A ). Conversely, on immunoprecipitation of the MasR from mesenteric vascular bed lysate, we observed coprecipitation of the B 2 R with 2 bands detected in this situation ( Figure 6B ).The lower band may correspond to the immature B 2 R, as previously suggested. 23 To further confirm B 2 R-MasR interaction, we performed proximity ligation assay (PLA). Human glomerular 
Discussion
The present study demonstrates that B 2 R and MasR form constitutive and agonist-independent functional heteromers. The results of coimmunoprecipitation experiments in rat mesenteric vascular bed and of positive PLA in human glomerular endothelial cells provide direct evidence that these receptors also form heteromers in vivo (present results).
Previous studies have demonstrated the heteromerization of MasR with AT 1 R and that this heteromerization inhibited the actions of angiotensin II. 24 In this situation, MasR acts as a physiological antagonist of AT 1 R. B 2 R has been described to form constitutive heteromers with AT 1 R. AT 1 R-B 2 R heteromerization was shown to enhance AT 1 R-stimulated signaling under pathophysiological conditions such as experimental and human pregnancy hypertension. 25, 26 However, the universality of the formation of AT 1 R-B 2 R heteromers has been questioned. 6 B 2 R also forms heteromers with B 1 R in cotransfected HEK293 cells and in natively expressing endothelial cells, resulting in significant internalization and desensitization of the B 1 R response in cells pretreated with the B 2 R agonist. 27 Concerning B 2 R and MasR, to our knowledge, this is the first evidence showing B 2 R-MasR heteromerization, which is constitutive and independent of the presence of physiological ligands. B 2 R-MasR heteromerization may explain the potentiation in bradykinin or Ang-(1-7) responses when both ligands are incubated together. 6, [8] [9] [10] [11] 28 We could not disregard that bradykinin-Ang-(1-7) interaction may result not only from B 2 R-MasR heteromerization but also from ACE inactivation by Ang- (1-7) . It has been shown that Ang-(1-7) at micromolar levels inhibits ACE, thus enhancing bradykinin vasodilatory effects. 11, 29, 30 In contrast, the addition of B 2 R or MasR antagonists decreased FRET efficiency to ≈50% of the initial value, suggesting that the antagonist promoted the dissociation of the heteromer and that the formation of B 2 R-MasR heteromer is essential for agonists to display many of its biological responses. For instance, bradykinin or Ang-(1-7) induced an antiproliferative response when B 2 RMasR heteromer is formed and not when each receptor (B 2 R or MasR) is expressed alone (present results) showing the importance of this interaction for some of the effects elicited by bradykinin or Ang-(1-7). B 2 R-MasR heteromerization may also explain the lack of effect of Ang-(1-7) when B 2 R is blocked [13] [14] [15] or the absence of the bradykinin-induced vasodilatory response when MasR is knocked down. 12 In agreement, our present study shows that the Ang-(1-7)-induced increase in AA release or in ERK phosphorylation was prevented by the B 2 R antagonist or that the bradykininstimulated Akt phosphorylation was prevented by the MasR antagonist.
Heteromerization may result in changes in affinity for a specific ligand, receptor trafficking, maturation, and signaling. [17] [18] [19] Several reports demonstrated changes in pharmacological properties of the receptors because of heteromerization. Our present study showed that the coexpression of B 2 R leads to an increase in the affinity of Ang-(1-7) for its receptor Mas, although the vice versa situation was not observed. This result may explain the potentiation in the vasodilatory or blood pressure-lowering responses when bradykinin and Ang-(1-7) are present together. 6, [8] [9] [10] [11] 28 A receptor that is capable of producing a biological response in the absence of a bound ligand is said to display constitutive activity. Our study showed that constitutive ERK or Akt activarion was not modified by B 2 R-MasR heteromerization. Conversely, AA release was increased 2-fold in cells expressing both B2R and MasR. We may speculate that in this last situation not only receptor heteromerization but also a cross talk between both receptors may occur, and this may explain the increase in AA release. B 2 R-MasR heteromerization also influences downstream signaling. Our present study showed that B 2 R-MasR heteromerization induced a greater response concerning AA release and ERK phosphorylation on Ang-(1-7) stimulation. Furthermore, bradykinin-stimulated Akt phosphorylation only when both B 2 R and MasR were coexpressed but not when the B 2 R was expressed alone, suggesting that this was a biochemical fingerprint associated to the heteromer because it was abolished when heteromerization was disrupted by the cross-antagonist. For instance, β1-adrenergic receptor (AR)-β2-AR heteromerization induced a reduced ability of the β2-AR to stimulate ERK-phosphorylation 31 or the AT 1 R-D 2 R heteromerization affected calcium mobilization but not cAMP signaling coupled to AT1R. 32 In both examples as it happens in B 2 R-MasR heteromerization (present results) 1 receptor modifies downstream signaling of the partner receptor, giving a biochemical fingerprint, which is characteristic of receptor heteromerization. 33 Akt phosphorylation is one of the downstream signaling mediating Ang-(1-7) actions in cultured cells and tissues. 1, 2 It was surprising to find that Ang-(1-7) stimulation did not elicit Akt activation (present results). Despite that, constitutive Akt activation was present in MasR-transfected cells, suggesting that MasR activation is coupled to Akt activation despite the fact that Ang-(1-7) was absent. We do not have an explanation for the absence of effect of Ang-(1-7) on Akt phosphorylation. Conversely, it does not imply that B 2 R-MasR interaction does not take place in nontransfected cells because in the present work we provide evidence that this interaction occurs in vascular bed from rats and in renal cells from humans.
Receptor endocytosis serves a variety of purposes, including receptor downregulation, recycling, and relocalization of the cell signaling. B 2 R follows an internalization pathway involving redistribution to caveolae, through an arrestin-and dynamin-independent pathway. 34 However, other evidence showed that B 2 R was targeted to early endosome after agonist stimulation. 35 MasR is internalized on ligand stimulation into early endosomes via a clathrin-dependent pathway. 20 Our study showed that B 2 R-MasR heteromer was internalized mostly into early endosomes and that stimulation of only one of the receptors was sufficient to promote cointernalization of the entire dimer, reinforcing the concept not only of B 2 R-MasR heteromer formation but also of cointernalization on agonist stimulation.
Heteromerization of GPCRs can affect the internalization properties of the individual receptors. 17 Our present data demonstrate that B 2 R-MasR heteromerization results in a delayed sequestration of the MasR when stimulated with its ligand Ang-(1-7). Similar observations were made for other GPCRs. [36] [37] [38] Rapid desensitization and receptor internalization and trafficking tightly control the temporal and spatial regulation of GPCR signaling and hence the biological response. Both B 2 R and MasR have been associated with cardioprotective, vasodilatory, and hypotensive responses. [1] [2] [3] [4] [5] In addition, the present study showed that Ang-(1-7) induced antiproliferative responses when B 2 R-MasR heteromer was formed but not when MasR is expressed alone. The delayed sequestration of MasR may cause this receptor to be present for a longer time in the plasma membrane, thus allowing a long-lasting protective response.
Conclusions
In conclusion, we have demonstrated that B 2 R and MasR can form heteromers that are internalized on agonist stimulation. This heteromer revealed a delayed sequestration of the MasR on stimulation with Ang- (1-7) . Furthermore, B 2 R coexpression induced an increase in the affinity ligand binding properties of MasR. Altogether, these changes in receptor functional characteristics may lead to long-lasting protective 
Ligand concentrations
Concentrations of 1 µmol/L of BK or Ang-(1-7) were employed in the present study. Due to the short half-life of BK and Ang-(1-7) (less than 1 min), high concentrations of these peptides was employed just to assure that they reach the receptors in amount enough to measure a response. Many researchers have employed those concentrations used in our study.
3-12 Furthermore, we have previously used high concentrations of Ang-(1-7 to induce R desensitization followed by R internalization. 1 In order to not change ligand concentration, we performed the rest of the experiments with the same concentration as the first ones, that is 1 µmol/L.
Animals
Male Wistar rats weighting 300-350 g were used (n=5) were used for coimmunoprecitipation study. Animals were handled in accordance with the National Institutes of Health's animal care guidelines. The animal research protocol was approved by the Institutional Animals Care and Use Committee of the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.
FRET quantification by Acceptor Photobleaching
HEK293T cells cotransfected with B2R-CFP and MasR-YFP cDNA were fixed and analyzed for the presence of FRET using APB. 13 Microscopy images were acquired by a confocal scanning microscope (Spectral FV1000 Olympus) using a 60X UPLSAPO oil immersion objective lens with a numerical aperture of 1.35. The samples were excited for ECFP and EYFP with the 457 nm and 488 nm lines of an argon laser, respectively, in sequential mode. The samples were illuminated through the 457/488 dichroic filter and the emission was collected in the 465-495 nm band for ECFP and 500-530 nm band for EYFP. The intensity of the donor molecule was imaged before (D) and after (Dapb) photobleaching of the acceptor molecule. To control for unwanted photodestruction of the donor during imaging, two images were acquired in each case. The background intensity in each image was measured from the mean intensity of a region without cells, and subtracted from the images for all subsequent calculations. Cells exhibiting large decrease in the donor intensity (> 5%) due to imaging bleaching, as measured from two consecutive images, were discarded. For the remaining cells, FRET efficiency was calculated in each pixel as 1 -D/Dapb. The number of cells analyzed per experiment was 25. Results were expressed as apparent FRET efficiency (AFE), where AFE = 1 -(donor intensity before photobleaching) / (donor intensity after photobleaching).
transfected cells: 15000 cpm of specific binding vs B2R-CFP transfected cells: 45000 cpm specific binding). After being stimulated by its ligand, B2 receptor is endocytosed. We evaluated the functionality of B2R-CFP by measuring B2R-CFP internalization upon ligand exposure. Figure S1C shows that B2R-CFP receptor is endocytosed after ligand stimulation. Receptor functionality and coupling were evaluated by measuring B2 receptor signaling. To determine the functionality of B2R-CFP, HEK293T cells transfected with the B2R-CFP construct and labeled with [ 3 H]AA were exposed to BK during different times. As shown in Figure S1D , 500 nmol/L BK caused an increase in [ 3 H]AA release in B2R-CFP transfected cells after 30 min stimulation. Cells transfected with the empty vector (mock) showed no change in [ 3 H]AA release upon BK stimulation ( Figure S1C ). Collectively, these data show that B2R-CFP is properly expressed and fully active. Regarding the fusion protein MasR-YFP, we have previously shown that the YFP fused to the C terminus of MasR does not alter its functional properties. 
Coimmuprecipitation control
As a control, immunoprecipitation in HEK293T cells lacking one of the receptors was performed. As it is shown in Figure S4A , immunoprecipitation performed with an antiMasR antibody in cells expressing only B2R did not cause B2R immunoprecipitation. Conversely, in cells coexpressing both B2R and MasR, immunoprecipitation performed with an anti-MasR antibody caused B2R coimmunoprecipitation. These results confirm those observed in rat mesenteric vascular bed. 
